MX9704727A - Composicion para el tratamiento de tumores malignos y sus metastasis. - Google Patents

Composicion para el tratamiento de tumores malignos y sus metastasis.

Info

Publication number
MX9704727A
MX9704727A MX9704727A MX9704727A MX9704727A MX 9704727 A MX9704727 A MX 9704727A MX 9704727 A MX9704727 A MX 9704727A MX 9704727 A MX9704727 A MX 9704727A MX 9704727 A MX9704727 A MX 9704727A
Authority
MX
Mexico
Prior art keywords
tumor
lactose
cytotoxic
malignant tumors
metastases
Prior art date
Application number
MX9704727A
Other languages
English (en)
Other versions
MXPA97004727A (es
Inventor
David Rubin
Original Assignee
Co Enzyme Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Co Enzyme Technology Ltd filed Critical Co Enzyme Technology Ltd
Publication of MX9704727A publication Critical patent/MX9704727A/es
Publication of MXPA97004727A publication Critical patent/MXPA97004727A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se puede inhibir la formacion de metastasis de tumores malignos administrando a un paciente que tenga necesidad de ello, suficiente lactosa para bloquear las lectinas cruciales en el organo afectado, de manera que las células tumorales no pueden anclarse a otros lugares del cuerpo. Se puede administrar la lactosa sola o en combinacion con conjugados o fármacos citotoxicos. De preferencia se conjuga la lactosa con un sustancia citotoxica, de manera que se trate el tumor primario circurrentemente con la prevencion de la metastasis. Adicionalmente, al conjugar un fármaco citotoxico con la lactosa, se mantiene el fármaco citotoxico en proximidad íntima con el tumor, debido a los receptores en el tumor, que unen la lactosa (y, por consiguiente, el agente citotoxico unido a ella) a las células tumorales. Al utilizar un conjugado de lactosa con un agente citotoxico, generalmente es suficiente una dosis para destruir los sitios receptores en el tumor y prevenir la metastasis del tumor, al mismo tiempo que se trata el tumor.
MXPA/A/1997/004727A 1994-12-21 1995-11-27 Composicion para el tratamiento de tumoresmalignos y sus metastasis MXPA97004727A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/360,352 US5639737A (en) 1991-11-04 1994-12-21 Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors
US08360352 1994-12-21

Publications (2)

Publication Number Publication Date
MX9704727A true MX9704727A (es) 1998-06-30
MXPA97004727A MXPA97004727A (es) 1998-10-30

Family

ID=

Also Published As

Publication number Publication date
EP0797453A1 (en) 1997-10-01
EP0797453B1 (en) 2003-03-26
DE69530109T2 (de) 2004-02-05
AU692021B2 (en) 1998-05-28
IL116465A0 (en) 1996-03-31
DE69530109D1 (de) 2003-04-30
IL116465A (en) 2010-04-29
CA2208206C (en) 2008-02-12
CA2208206A1 (en) 1996-06-27
ATE235257T1 (de) 2003-04-15
WO1996019243A1 (en) 1996-06-27
US5639737A (en) 1997-06-17
AU4240796A (en) 1996-07-10

Similar Documents

Publication Publication Date Title
IL116465A0 (en) Pharmaceutical antitumor composition
Laske et al. Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice
Goff et al. Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model
HK1046093A1 (en) Docetaxel in combination with rhumab her2 for the treatment of cancers.
Rowland et al. Antitumor properties of vindesine-monoclonal antibody conjugates
EP1434603A4 (en) METHOD OF TREATMENT USING LIGAND-IMMUNOGENE CONJUGATES
TR200202231T2 (tr) Amiloidojenik hastalığın önlenmesi ve tedavisi
GEP20043251B (en) Use of CYP2D6 Inhibitors in Combination Therapies
Shiah et al. Antitumor activity of N-(2-hydroxypropyl) methacrylamide copolymer-mesochlorin e6 and adriamycin conjugates in combination treatments
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
EP0740650A4 (en) CO-MEDICINAL PRODUCTS USED AS A REGULATED MEDICINE DELIVERY PROCESS
YU77000A (sh) Primena peg-ifn-alfa i ribavirina za lečenje hroničnog hepatitisa c
HRP20080598T3 (en) Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
IL182352A0 (en) The use of et-743 in the preparation of a medicament for treating cancer and medical kits containing et-743
WO1999056723A3 (en) Hemoglobine-haptoglobin complexes for targeted drug delivery
AR016427A1 (es) CONJUGADOS uTILES PARA EL TRATAMIENTO DE CÁNCER DE PRoSTATA, Y UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE.
Pearson et al. Chemoimmunotoxin therapy against a human colon tumor (HT-29) xenografted into nude mice
Myklebust et al. Targeted therapy with immunotoxins in a nude rat model for leptomeningeal growth of human small cell lung cancer
Abbas et al. Antibody‐Drug Conjugates Used in Breast Cancers
WO2000006136A3 (en) Therapeutic combination of polyamine with an anticancer agent
Prados Temozolomide in combination with other cytotoxic agents
RU2002103808A (ru) Способ лечения болевого синдрома у онкологических больных
JPH0455172B2 (es)
CA2343120A1 (en) Use of an anthracycline derivative for the treatment of a liver tumor
ATE411051T1 (de) Polypeptid, dessen konjugat doxorubicin enthält, und auf diesem basierende pharmazeutische zusammensetzung